2022 Deal-Making Momentum To Be Driven By Small Companies

Licensing, Partnerships Preferred Over Acquisitions?

The power dynamics for deal-making in 2022 may shift to smaller companies emboldened by funds from venture financing and IPOs. While the spotlight will continue to be on ADCs and cell and gene therapies, vaccines and COVID-19 treatments will predictably be hot areas for licensing, Syneos Health predicts.

Partnerships, Smaller Deals To Dominate In 2022? • Source: Alamy

Smaller companies are seen taking the driver’s seat in deal-making during 2022 while the traditional deal initiators - large biopharma companies - are expected to slow down, a new survey shows. 

Overall, deal flow sentiment for 2022 suggests an increase over the previous year, though not to the levels seen for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip